Symrise (FRA:SY1) Given a €81.00 Price Target at Morgan Stanley

Morgan Stanley set a €81.00 ($94.19) target price on Symrise (FRA:SY1) in a research note issued to investors on Monday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

A number of other brokerages have also recently commented on SY1. Baader Bank set a €53.00 ($61.63) price objective on Compugroup Medical and gave the stock a neutral rating in a research note on Tuesday, April 30th. UBS Group boosted their price objective on LyondellBasell Industries from $86.00 to $89.00 and gave the stock a neutral rating in a research note on Thursday, July 11th. Barclays restated a hold rating and set a $52.00 price objective on shares of Biohaven Pharmaceutical in a research note on Tuesday, March 19th. Deutsche Bank upgraded SUN ART RETAIL/ADR from a hold rating to a buy rating in a research note on Wednesday, July 3rd. Finally, Kepler Capital Markets restated a buy rating and set a $134.00 price objective on shares of Airbus in a research note on Tuesday, April 30th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of €79.50 ($92.44).

Shares of Symrise stock opened at €83.32 ($96.88) on Monday. Symrise has a twelve month low of €56.96 ($66.23) and a twelve month high of €73.48 ($85.44). The firm has a fifty day moving average price of €85.49.

About Symrise

Symrise AG develops, produces, and sells fragrances, flavorings, and cosmetic ingredients. It operates through three segments: Scent & Care, Flavor, and Nutrition. The Scent & Care segment develops, produces, and sells fragrance ingredients and compositions, cosmetic ingredients, and mint flours, as well as specific application processes for such substances.

Further Reading: How to Track your Portfolio in Google Finance

Analyst Recommendations for Symrise (FRA:SY1)

Receive News & Ratings for Symrise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symrise and related companies with MarketBeat.com's FREE daily email newsletter.